Expected Milestones

Q3 2023 Expect waiver of further animal pulmonary toxicology and approval early Phase Clinical Trials of antiviral CVX 20733 in Nepal and India
Confirm DPI Manufacturer for CVX 20733
Q4 2023 Commence Pre-Phase I Pharmacokinetic) studies of CVX 20733 in healthy volunteers (Australia or Nepal & India)
Combine Phase I Dose escalation Study of CVX 20733 in Healthy Volunteers (Nepal and India)
Q4 2023 Explore formal listing on Australian, Asian or North-American Stock Exchange
Q1 2024 Commence Phase II Clinical Trial of Nebulised CVX 20733 in the following cohorts: non-isolated hospitalized infection+ individuals; hospitalized non-ventilated infection+ve patients
Q3 2024 Phase III for CVX 20733 targeting: isolated non-hospitalised infection+ve patients and hospitalised non- ventilated infection+ve patients
* The projected timelines are fluid and depend primarily on the initial validation studies of anti-viral activity being completed on time. While timeline delays are possible, the successful completion of these initial studies, together with commensurate investment, will permit many of the subsequent pre-clinical tests to be carried out concomitantly, so as to accelerate the necessary clinical trials.

2023-2024 Expected Milestones